Anti-HLA-DRB/HLA-DRB1 therapeutic antibody (Pre-made Apolizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers. Development was abandoned in 25 because of toxic effects and lack of efficacy in human patients. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia. There are no current clinical trials into its use.